Chukwu Obinna 
OSUN, Nigeria – Nigeria launches its first immunotherapy clinical trial, offering free, cutting-edge treatment to colorectal cancer patients in a landmark step for cancer care in sub-Saharan Africa.
The trial, unveiled on Wednesday at Obafemi Awolowo University Teaching Hospital (OAUTH) in Ile-Ife, brings together Nigerian institutions and the United States-based Memorial Sloan Kettering Cancer Centre.
Lead investigator Professor Olusegun Alatise describes the programme as a turning point in a country where colorectal cancer survival rates remain critically low.
“This trial opens new hope for patients whose genetic profiles limit standard treatment options,” Alatise says.
The study focuses on PD-1 blockade immunotherapy for patients with mismatch-repair-deficient colorectal cancer, a method that activates the body’s immune system rather than relying solely on chemotherapy or surgery.
Eligible patients receive treatment at no cost at OAUTH, Lagos University Teaching Hospital, and Medserve’s NSIA Diagnostic Centre in Lagos.
Regulatory approvals come from NAFDAC and the National Health Research Ethics Committee, ensuring compliance with global ethical standards.
“This is the first immunotherapy trial of its kind in Nigeria,” Alatise says. “It reflects a global partnership committed to equity in cancer treatment.”
Memorial Sloan Kettering serves as study sponsor and data coordinating centre, while BeOne Medicines supplies the immunotherapy drug tislelizumab. BioVentures for Global Health supports regulatory processes.
The announcement coincides with World Cancer Day, underscoring renewed urgency as late diagnosis continues to drive high mortality.
Experts say the trial could redefine cancer treatment access in Nigeria and offer a scalable model for Africa, where advanced therapies remain largely inaccessible.
About the Author
Oluwatobi Adu 
Oluwafunbi Bello